Details
| Originalsprache | Englisch |
|---|---|
| Titel des Sammelwerks | Bioreactor Systems for Tissue Engineering II |
| Seiten | 29-54 |
| Seitenumfang | 26 |
| Publikationsstatus | Veröffentlicht - 2010 |
Publikationsreihe
| Name | Advances in Biochemical Engineering/Biotechnology |
|---|---|
| Band | 123 |
| ISSN (Print) | 0724-6145 |
Abstract
Mesenchymal stem or stromal cells (MSCs) have a high potential for cell-based therapies as well as for tissue engineering applications. Since Friedenstein first isolated stem or precursor cells from the human bone marrow (BM) stroma that were capable of osteogenesis, BM is currently the most common source for MSCs. However, BM presents several disadvantages, namely low frequency of MSCs, high donor-dependent variations in quality, and painful invasive intervention. Thus, tremendous research efforts have been observed during recent years to find alternative sources for MSCs. In this context, the human umbilical cord (UC) has gained more and more attention. Since the UC is discarded after birth, the cells are easily accessible without ethical concerns. This postnatal organ was found to be rich in primitive stromal cells showing typical characteristics of bone-marrow MSCs (BMSCs), e.g., they grow as plastic-adherent cells with a fibroblastic morphology, express a set of typical surface markers, and can be directly differentiated at least along mesodermal lineages. Compared to BM, the UC tissue bears a higher frequency of stromal cells with a higher in vitro expansion potential. Furthermore, immune-privileged and immune-modulatory properties are reported for UC-derived cells, which open highly interesting perspectives for clinical applications.
ASJC Scopus Sachgebiete
- Biochemie, Genetik und Molekularbiologie (insg.)
- Biotechnologie
- Chemische Verfahrenstechnik (insg.)
- Bioengineering
- Immunologie und Mikrobiologie (insg.)
- Angewandte Mikrobiologie und Biotechnologie
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
Bioreactor Systems for Tissue Engineering II. 2010. S. 29-54 (Advances in Biochemical Engineering/Biotechnology; Band 123).
Publikation: Beitrag in Buch/Bericht/Sammelwerk/Konferenzband › Beitrag in Buch/Sammelwerk › Forschung › Peer-Review
}
TY - CHAP
T1 - Mesenchymal stromal cells derived from human umbilical cord tissues
T2 - Primitive cells with potential for clinical and tissue engineering applications
AU - Moretti, Pierre
AU - Hatlapatka, Tim
AU - Marten, Dana
AU - Lavrentieva, Antonina
AU - Majore, Ingrida
AU - Hass, Ralf
AU - Kasper, Cornelia
N1 - Copyright: Copyright 2014 Elsevier B.V., All rights reserved.
PY - 2010
Y1 - 2010
N2 - Mesenchymal stem or stromal cells (MSCs) have a high potential for cell-based therapies as well as for tissue engineering applications. Since Friedenstein first isolated stem or precursor cells from the human bone marrow (BM) stroma that were capable of osteogenesis, BM is currently the most common source for MSCs. However, BM presents several disadvantages, namely low frequency of MSCs, high donor-dependent variations in quality, and painful invasive intervention. Thus, tremendous research efforts have been observed during recent years to find alternative sources for MSCs. In this context, the human umbilical cord (UC) has gained more and more attention. Since the UC is discarded after birth, the cells are easily accessible without ethical concerns. This postnatal organ was found to be rich in primitive stromal cells showing typical characteristics of bone-marrow MSCs (BMSCs), e.g., they grow as plastic-adherent cells with a fibroblastic morphology, express a set of typical surface markers, and can be directly differentiated at least along mesodermal lineages. Compared to BM, the UC tissue bears a higher frequency of stromal cells with a higher in vitro expansion potential. Furthermore, immune-privileged and immune-modulatory properties are reported for UC-derived cells, which open highly interesting perspectives for clinical applications.
AB - Mesenchymal stem or stromal cells (MSCs) have a high potential for cell-based therapies as well as for tissue engineering applications. Since Friedenstein first isolated stem or precursor cells from the human bone marrow (BM) stroma that were capable of osteogenesis, BM is currently the most common source for MSCs. However, BM presents several disadvantages, namely low frequency of MSCs, high donor-dependent variations in quality, and painful invasive intervention. Thus, tremendous research efforts have been observed during recent years to find alternative sources for MSCs. In this context, the human umbilical cord (UC) has gained more and more attention. Since the UC is discarded after birth, the cells are easily accessible without ethical concerns. This postnatal organ was found to be rich in primitive stromal cells showing typical characteristics of bone-marrow MSCs (BMSCs), e.g., they grow as plastic-adherent cells with a fibroblastic morphology, express a set of typical surface markers, and can be directly differentiated at least along mesodermal lineages. Compared to BM, the UC tissue bears a higher frequency of stromal cells with a higher in vitro expansion potential. Furthermore, immune-privileged and immune-modulatory properties are reported for UC-derived cells, which open highly interesting perspectives for clinical applications.
KW - Counterflow centrifugal elutriation
KW - Mesenchymal stem cell
KW - Mesenchymal stromal cell
KW - MSC
KW - Umbilical cord
UR - http://www.scopus.com/inward/record.url?scp=82055168913&partnerID=8YFLogxK
U2 - 10.1007/10_2009_15
DO - 10.1007/10_2009_15
M3 - Contribution to book/anthology
C2 - 20012739
AN - SCOPUS:82055168913
SN - 9783642160509
T3 - Advances in Biochemical Engineering/Biotechnology
SP - 29
EP - 54
BT - Bioreactor Systems for Tissue Engineering II
ER -